CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as...

CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board
as Clinical Consultant

BOTHELL, Wash., May 20 /PRNewswire-FirstCall/ -- CellCyte Genetics
Corporation (CellCyte) (OTC Bulletin Board: CCYG) today announced the
appointment of Jay H. Traverse, M.D., FACC, FAHA, to its Scientific Advisory
Board as a clinical consultant. Traverse is an interventional cardiologist
with the Minneapolis Heart Institute at Abbott Northwestern Hospital with
extensive experience in cardiovascular stem cell clinical trial research.
"We are delighted to welcome Dr. Traverse to our Scientific Advisory
Board," said Ronald W. Berninger, Ph.D., Chief Scientific Officer at CellCyte.
"His experience and knowledge will be a tremendous asset to CellCyte as we
develop and implement our clinical trial strategy for our lead compound,
CCG-TH30."
Dr. Traverse received his M.D. from Case Western Reserve University
Medical School and is currently an Interventional Cardiologist and Associate
Professor of Medicine in the Department of Cardiology at the University of
Minnesota. He joined the Minneapolis Heart Institute immediately upon
finishing his training in 1996. His clinical interests include cell therapy
administration in chronic ischemic heart disease and following acute
myocardial infarction, angiogenesis and mitigation of reperfusion injury.
Traverse is a member of numerous professional associations including American
College of Cardiology (ACC), Society for Cardiac Angiography and Interventions
(SCAI), American Heart Association's (AHA) Council on Basic Cardiovascular
Science, and the American Physiological Society.
About CellCyte Genetics
CellCyte Genetics is a biotechnology company engaged in the discovery,
development and commercialization of stem cell enabling therapeutic products.
CellCyte is developing products designed to allow more efficient delivery and
increased retention of adult stem cells to diseased organs, such as the heart.
The goal of these therapies is to increase the number of stem cells delivered
to a damaged organ, thereby markedly increasing organ healing and functional
restoration. The Company's lead product in development, CCG-TH30, is designed
to send autologous bone marrow-derived (adult) stem cells to the heart of
patients after a heart attack. CellCyte Genetics | 1725 220th Street SE |
Bothell | Washington | 98021 | US
For further information see: www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS
DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL,
ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS,
PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE
HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS
RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS
AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM
ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH
STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS
THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE,"
"ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE
FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE,
BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT
OF CCG-TH30. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL
PROCESS, COMPETITIVE PRODUCTS AND COMPANIES AND THE COMPANY'S ABILITY AND
LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO
ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY
WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS
ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO
OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS
WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING
STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS,
EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE,
THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR INTENTIONS
WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION
SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE
COMPANY'S PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT
REPORTS ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY
MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH
OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE
CONTENTS OF THIS NEWS RELEASE.
SOURCE CellCyte Genetics Corporation

Investor Relations of CellCyte Genetics Corporation, 1-877-688-5050,
Investorrelations@cellcyte.com